Drug Approval | February 05, 2026
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
For the full year FY25, net profit soared 12x to Rs 345 crore
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Subscribe To Our Newsletter & Stay Updated
